skip to main content
Show Results with:

Atorvastatin plus omega‐3 fatty acid ethyl ester decreases very‐low‐density lipoprotein triglyceride production in insulin resistant obese men

Ng, T. W. K. et al.

Diabetes, obesity & metabolism. Volume 16:Issue 6 (2014, June); pp 519-526 -- [John Wiley & Sons Ltd]

Online access

  • Title:
    Atorvastatin plus omega‐3 fatty acid ethyl ester decreases very‐low‐density lipoprotein triglyceride production in insulin resistant obese men
  • Author: Ng, T. W. K.;
    Ooi, E. M. M.;
    Watts, G. F.;
    Chan, D. C.;
    Barrett, P. H. R.
  • Found In: Diabetes, obesity & metabolism. Volume 16:Issue 6 (2014, June); pp 519-526
  • Journal Title: Diabetes, obesity & metabolism
  • Subjects: Clinical pharmacology--Periodicals; Diabetes--Periodicals; Metabolism--Disorders--Periodicals; Obesity--Periodicals; Dewey: 616.462
  • Rights: legaldeposit
  • Publication Details: [John Wiley & Sons Ltd]
  • Abstract: <x xml:space="preserve">Abstract</x> Aim

    To test the effect of atorvastatin (ATV) and ATV plus ω‐3 FAEEs on VLDL‐TG metabolism in obese, insulin resistant men.

    Methods

    We carried out a 6‐week randomized, placebo‐controlled study to examine the effect of ATV (40 mg/day) and ATV plus ω‐3 FAEEs (4 g/day) on VLDL‐TG metabolism in 36 insulin resistant obese men. VLDL‐TG kinetics were determined using d5‐glycerol, gas chromatography–mass spectrometry and compartmental modelling.

    Results

    Compared with the placebo, ATV significantly decreased VLDL‐TG concentration (−40%, p < 0.001) by increasing VLDL‐TG fractional catabolic rate (FCR) (+47%, p < 0.01). ATV plus ω‐3 FAEEs lowered VLDL‐TG concentration to a greater degree compared with placebo (−46%, p < 0.001) or ATV monotherapy (−13%, p = 0.04). This was achieved by a reduction in VLDL‐TG production rate (PR) compared with placebo (−32%, p = 0.008) or ATV (−20%, p = 0.03) as well as a reciprocal increase in VLDL‐TG FCR (+42%, p < 0.05) compared with placebo.

    Conclusion

    In insulin resistant, dyslipidaemic, obese men, ATV improves VLDL‐TG metabolism by increasing VLDL‐TG FCR. The addition of 4 g/day ω‐3 FAEE to statin therapy provides further TG‐lowering by lowering VLDL‐TG PR.


  • Identifier: ETOClsidyv8914b24c; System Number: LDEAvdc_100024825355.0x000001; Journal ISSN: 1462-8902; 10.1111/dom.12243
  • Publication Date: 2014
  • Physical Description: Electronic
  • Shelfmark(s): ELD Digital store

Searching Remote Databases, Please Wait